Expanded Bexxar Use

On the heels of Bexxar's complete transfer from Corixa to GSK comes this press release:

The BEXXAR Therapeutic Regimen is now indicated for the treatment of patients with CD-20 antigen expressing relapsed or refractory (nonresponsive), low-grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with Rituxan (Rituximab) refractory non-Hodgkin's lymphoma. The original indication specified that patients have disease that was refractory to Rituxan and had relapsed following chemotherapy. Determination of the effectiveness of the BEXXAR Therapeutic Regimen was based on overall response rates in patients whose disease is refractory to chemotherapy alone or to chemotherapy and Rituxan.

So now patients who fall into the types of NHL that can be treated with Bexxar do not have to show that Rituxan has been tried and failed before trying Bexxar. Yahoo Press Release

LymphomaInfo Social